Maylan gets favourable ruling on one more patent of Copaxone

The company, which is Natco Pharma's marketing partner, hopes to translate this potential para-4 filing into a product launch after clearing legal hurdles

Natco Pharma Limited on Friday announced that the US Patent and Trademark Office has ruled in favour of its marketing partner Mylan in its new trial proceedings over the claims of a third patent of multiple scleroses drug Copaxone 40 mg/ml and found the claims unpatentable.

On August 24, the US Patent Office ruled in favour of Mylan on claims of two patents of blockbuster drug Copaxone.

The company hopes to translate this potential para-4 filing into the launch after clearing the legal hurdles one by one. Israeli generic pharmaceutical major Teva owns the drug.

It had launched the long working Copaxone 40 mg/ml injection closer to the expiry of Copaxone 20 mg/ml, which already have generic equivalents available in the US market.